Personalis secures $50M Merck investment, extends Moderna pact, expands Tempus deal

Personalis, Inc.

Merck to purchase 14,044,943 shares at $3.56/share for ~$50M; closing expected Dec 19, 2024.
Merck receives standstill, information, pro-rata participation, and voting rights until 2 years post-close.
Tempus AI authorized to sell NeXT Personal minimal residual disease test to pharma/biotech clients.
Moderna extends SOW for V940/mRNA-4157 INT program to up to 10 years; Moderna can license IP for low double-digit millions.
Personalis to use $10M of proceeds to open ISO-certified lab outside US, mutually agreed with Merck.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.